

# Philip H Elsinga

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4007146/publications.pdf>

Version: 2024-02-01

177  
papers

5,957  
citations

66343

42  
h-index

91884

69  
g-index

185  
all docs

185  
docs citations

185  
times ranked

6058  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Testâ€“retest reproducibility of cerebral adenosine A2A receptor quantification using [11C]preladenant. <i>Annals of Nuclear Medicine</i> , 2022, 36, 15-23.   | 2.2  | 0         |
| 2  | Pharmacokinetic Modeling of [ <sup>11</sup> C]GSK-189254, PET Tracer Targeting H <sub>3</sub> Receptors, in Rat Brain. <i>Molecular Pharmaceutics</i> , 2022, 19, 918-928.   | 4.6  | 1         |
| 3  | A proof-of-concept study on the use of a fluorescein-based 18F-tracer for pretargeted PET. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2022, 7, 3.   | 3.9  | 1         |
| 4  | EANM guideline on quality risk management for radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3353-3364.   | 6.4  | 11        |
| 5  | Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer. <i>Cancers</i> , 2022, 14, 1924.  | 3.7  | 5         |
| 6  | Potential PET tracers for imaging of tumor-associated macrophages. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2022, 7, 11.  | 3.9  | 11        |
| 7  | Dose-response assessment of cerebral P-glycoprotein inhibition in vivo with [18F]MC225 and PET. <i>Journal of Controlled Release</i> , 2022, 347, 500-507.   | 9.9  | 7         |
| 8  | Highlight selection of radiochemistry and radiopharmacy developments by editorial board (Januaryâ€“June 2020). <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 5.   | 3.9  | 1         |
| 9  | Allosteric Interactions between Adenosine A2A and Dopamine D2 Receptors in Heteromeric Complexes: Biochemical and Pharmacological Characteristics, and Opportunities for PET Imaging. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1719.     | 4.1  | 17        |
| 10 | Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 8.  | 3.9  | 58        |
| 11 | Mapping Arginase Expression with <sup>18</sup> F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary Î±-Amino Acids. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1163-1170.   | 5.0  | 3         |
| 12 | Highlight selection of radiochemistry and radiopharmacy developments by editorial board. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 13.  | 3.9  | 1         |
| 13 | Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 768-773.  | 2.8  | 30        |
| 14 | Multivalent Probes in Molecular Imaging: Reality or Future?. <i>Trends in Molecular Medicine</i> , 2021, 27, 379-393.  | 6.7  | 14        |
| 15 | Spotlight on: guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals published in <i>EJNMMI Radiopharmacy and Chemistry</i> (2021)6:8. <i>Clinical and Translational Imaging</i> , 2021, 9, 281-282. | 2.1  | 2         |
| 16 | Ultrafast Photoclick Reaction for Selective <sup>18</sup> F-Positron Emission Tomography Tracer Synthesis in Flow. <i>Journal of the American Chemical Society</i> , 2021, 143, 10041-10047.   | 13.7 | 22        |
| 17 | Head-to-head comparison of (R)-[11C]verapamil and [18F]MC225 in non-human primates, tracers for measuring P-glycoprotein function. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4307-4317.                                    | 6.4  | 6         |
| 18 | Evaluation of P-glycoprotein function at the bloodâ€“brain barrier using [18F]MC225-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4105-4106.  | 6.4  | 7         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | <i>In Vivo</i> Induction of P-Glycoprotein Function can be Measured with [ <sup>18</sup> F]MC225 and PET. <i>Molecular Pharmaceutics</i> , 2021, 18, 3073-3085.   | 4.6 | 11        |
| 20 | A new approach to produce [18F]MC225 via one-step synthesis, a PET radiotracer for measuring P-gp function. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 24.  | 3.9 | 0         |
| 21 | [ <sup>18</sup> F]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats. <i>Molecular Pharmaceutics</i> , 2021, 18, 3378-3386.  | 4.6 | 8         |
| 22 | The effects of molar activity on [18F]FDOPA uptake in patients with neuroendocrine tumors. <i>EJNMMI Research</i> , 2021, 11, 88.   | 2.5 | 0         |
| 23 | Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112260.  | 5.6 | 7         |
| 24 | Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16 <sup>1</sup> 2-18F-Fluoro-5 $\alpha$ -Dihydrotestosterone. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1140-1145.  | 5.0 | 7         |
| 25 | Pharmacokinetic Modeling of [ <sup>11</sup> C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates. <i>Molecular Pharmaceutics</i> , 2021, 18, 416-428.  | 4.6 | 3         |
| 26 | EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 34.   | 3.9 | 26        |
| 27 | GMP Compliant Synthesis of [ <sup>18</sup> F]Canagliflozin, a Novel PET Tracer for the Sodium <sup>+</sup> Glucose Cotransporter 2. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 16641-16649.  | 6.4 | 2         |
| 28 | Production of Long-Acting CNGRC <sup>+</sup> CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110573.                                   | 1.9 | 1         |
| 29 | [18F]Atorvastatin: synthesis of a potential molecular imaging tool for the assessment of statin-related mechanisms of action. <i>EJNMMI Research</i> , 2020, 10, 34.  | 2.5 | 3         |
| 30 | Pharmacokinetic Modeling of [18F]MC225 for Quantification of the P-Glycoprotein Function at the Blood <sup>+</sup> Brain Barrier in Non-Human Primates with PET. <i>Molecular Pharmaceutics</i> , 2020, 17, 3477-3486.  | 4.6 | 14        |
| 31 | Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5291.   | 4.1 | 66        |
| 32 | EANM guideline on the validation of analytical methods for radiopharmaceuticals. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 7.  | 3.9 | 57        |
| 33 | Focused ultrasound for opening blood-brain barrier and drug delivery monitored with positron emission tomography. <i>Journal of Controlled Release</i> , 2020, 324, 303-316.  | 9.9 | 41        |
| 34 | Development and Evaluation of Interleukin-2 <sup>+</sup> Derived Radiotracers for PET Imaging of T Cells in Mice. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1355-1360.   | 5.0 | 32        |
| 35 | Test <sup>+</sup> Retest Repeatability of [18F]MC225-PET in Rodents: A Tracer for Imaging of P-gp Function. <i>ACS Chemical Neuroscience</i> , 2020, 11, 648-658.   | 3.5 | 8         |
| 36 | Modular Medical Imaging Agents Based on Azide <sup>+</sup> Alkyne Huisgen Cycloadditions: Synthesis and Pre <sup>+</sup> Clinical Evaluation of [ <sup>18</sup> F] <sup>+</sup> Labeled PSMA <sup>+</sup> Tracers for Prostate Cancer Imaging. <i>Chemistry - A European Journal</i> , 2020, 26, 10871-10881. | 3.3 | 13        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Synthesis and Evaluation of [ <sup>18</sup> F]FETLos and [ <sup>18</sup> F]AMBF3Los as Novel <sup>18</sup> F-Labelled Losartan Derivatives for Molecular Imaging of Angiotensin II Type 1 Receptors. <i>Molecules</i> , 2020, 25, 1872. | 3.8  | 3         |
| 38 | <i>In vitro</i> studies on CNGRC-CPG2 fusion proteins for ligand-directed enzyme prodrug therapy for targeted cancer therapy. <i>Oncotarget</i> , 2020, 11, 619-633.  | 1.8  | 4         |
| 39 | Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. <i>EJNMMI Physics</i> , 2019, 6, 6.  | 2.7  | 0         |
| 40 | Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 8.  | 3.9  | 0         |
| 41 | The new Regulation on clinical trials in relation to radiopharmaceuticals: when and how will it be implemented?. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 2.  | 3.9  | 9         |
| 42 | Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. <i>EJNMMI Research</i> , 2019, 9, 34.  | 2.5  | 0         |
| 43 | Synthesis of Substituted Benzaldehydes via a Two-Step, One-Pot Reduction/Cross-Coupling Procedure. <i>Organic Letters</i> , 2019, 21, 4087-4091.  | 4.6  | 6         |
| 44 | Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. <i>European Journal of Hybrid Imaging</i> , 2019, 3, 6.  | 1.5  | 0         |
| 45 | Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1399-1399.   | 6.4  | 2         |
| 46 | MCR Scaffolds Get Hotter with <sup>18</sup> F-Labeling. <i>Molecules</i> , 2019, 24, 1327.  | 3.8  | 17        |
| 47 | [ <sup>18</sup> F]Fluoroethoxybenzovesamicol in Parkinson's disease patients: Quantification of a novel cholinergic positron emission tomography tracer. <i>Movement Disorders</i> , 2019, 34, 924-926.                                 | 3.9  | 20        |
| 48 | Late-Stage Copper-Catalyzed Radiofluorination of an Arylboronic Ester Derivative of Atorvastatin. <i>Molecules</i> , 2019, 24, 4210.  | 3.8  | 15        |
| 49 | Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging. <i>Medicinal Research Reviews</i> , 2019, 39, 1014-1052.    | 10.5 | 22        |
| 50 | Production of α-biobetter-β-glucosidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 127, 79-91.               | 4.0  | 21        |
| 51 | Avenues to molecular imaging of dying cells: Focus on cancer. <i>Medicinal Research Reviews</i> , 2018, 38, 1713-1768.  | 10.5 | 30        |
| 52 | Potential Therapeutic Applications of Adenosine A <sub>2A</sub> Receptor Ligands and Opportunities for A <sub>2A</sub> Receptor Imaging. <i>Medicinal Research Reviews</i> , 2018, 38, 5-56.  | 10.5 | 35        |
| 53 | Improving metabolic stability of fluorine-18 labeled verapamil analogs. <i>Nuclear Medicine and Biology</i> , 2018, 64-65, 47-56.   | 0.6  | 7         |
| 54 | New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging). <i>Current Pharmaceutical Design</i> , 2018, 24, 1287-1303.   | 1.9  | 11        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | In vivo evaluation of [ <sup>11</sup> C]preladenant positron emission tomography for quantification of adenosine A <sub>2A</sub> receptors in the rat brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 577-589.  | 4.3  | 19        |
| 56 | Evaluation of [ <sup>18</sup> F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood-brain barrier in rats: Kinetics, metabolism, and selectivity. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1286-1298.   | 4.3  | 29        |
| 57 | In Vivo Evaluation of <sup>11</sup> C-Preladenant for PET Imaging of Adenosine A <sub>2A</sub> Receptors in the Conscious Monkey. <i>Journal of Nuclear Medicine</i> , 2017, 58, 762-767.   | 5.0  | 19        |
| 58 | Initial Evaluation of an Adenosine A <sub>2A</sub> Receptor Ligand, <sup>11</sup> C-Preladenant, in Healthy Human Subjects. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1464-1470.   | 5.0  | 23        |
| 59 | Radiation Dosimetry of a Novel Adenosine A <sub>2A</sub> Receptor Radioligand [ <sup>11</sup> C]Preladenant Based on PET/CT Imaging and Ex Vivo Biodistribution in Rats. <i>Molecular Imaging and Biology</i> , 2017, 19, 289-297.  | 2.6  | 15        |
| 60 | Oxygen Activated, Palladium Nanoparticle Catalyzed, Ultrafast Cross-Coupling of Organolithium Reagents. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 3354-3359.   | 13.8 | 62        |
| 61 | Structure-activity relationship study towards non-peptidic positron emission tomography (PET) radiotracer for gastrin releasing peptide receptors: Development of [ <sup>18</sup> F] (S)-3-(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy)pyridin-2-yl]cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl)ureido]propionamide.<br><i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 277-292. | 3.0  | 4         |
| 62 | In vitro imaging of bacteria using <sup>18</sup> F-fluorodeoxyglucose micro positron emission tomography. <i>Scientific Reports</i> , 2017, 7, 4973.  | 3.3  | 19        |
| 63 | Nomenclature for radiopharmaceuticals, consultation of your opinion!. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2017, 2, 1.   | 3.9  | 4         |
| 64 | Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood-Brain Barrier. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1925-1936.  | 3.5  | 8         |
| 65 | Preclinical Evaluation and Quantification of <sup>18</sup> F-Fluoroethyl and <sup>18</sup> F-Fluoropropyl Analogs of SCH442416 as Radioligands for PET Imaging of the Adenosine A <sub>2A</sub> Receptor in Rat Brain. <i>Journal of Nuclear Medicine</i> , 2017, 58, 466-472.  | 5.0  | 18        |
| 66 | Comparison of In Vitro Assays in Selecting Radiotracers for In Vivo P-Glycoprotein PET Imaging. <i>Pharmaceuticals</i> , 2017, 10, 76.  | 3.8  | 4         |
| 67 | Novel Approach to Repeated Arterial Blood Sampling in Small Animal PET: Application in a Test-Retest Study with the Adenosine A <sub>1</sub> Receptor Ligand [ <sup>11</sup> C]MPDX. <i>Molecular Imaging and Biology</i> , 2016, 18, 715-723.  | 2.6  | 7         |
| 68 | P-glycoprotein Function in the Rodent Brain Displays a Daily Rhythm, a Quantitative In Vivo PET Study. <i>AAPS Journal</i> , 2016, 18, 1524-1531.   | 4.4  | 21        |
| 69 | <sup>11</sup> C- and <sup>18</sup> F-Labeled Radioligands for P-glycoprotein Imaging by Positron Emission Tomography. <i>ChemMedChem</i> , 2016, 11, 108-118.   | 3.2  | 6         |
| 70 | Sigma-1 Agonist Binding in the Aging Rat Brain: a MicroPET Study with [ <sup>11</sup> C]SA4503. <i>Molecular Imaging and Biology</i> , 2016, 18, 588-597.   | 2.6  | 11        |
| 71 | PET Tracers for Imaging of ABC Transporters at the Blood-Brain Barrier: Principles and Strategies. <i>Current Pharmaceutical Design</i> , 2016, 22, 5779-5785.  | 1.9  | 24        |
| 72 | Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier. <i>Molecular Pharmaceutics</i> , 2015, 12, 2265-2275.   | 4.6  | 23        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | In Vivo Biodistribution of No-Carrier-Added 6-18F-Fluoro-3,4-Dihydroxy-L-Phenylalanine (18F-DOPA), Produced by a New Nucleophilic Substitution Approach, Compared with Carrier-Added 18F-DOPA, Prepared by Conventional Electrophilic Substitution. <i>Journal of Nuclear Medicine</i> , 2015, 56, 106-112.  | 5.0 | 60        |
| 74 | MicroPET Evaluation of a Hydroxamate-Based MMP Inhibitor, [18F]FB-ML5, in a Mouse Model of Cigarette Smoke-Induced Acute Airway Inflammation. <i>Molecular Imaging and Biology</i> , 2015, 17, 680-687.  | 2.6 | 5         |
| 75 | Feasibility of [18F]-RGD for ex vivo imaging of atherosclerosis in detection of $\alpha_5\beta_1$ integrin expression. <i>Journal of Nuclear Cardiology</i> , 2015, 22, 1179-1186.   | 2.1 | 32        |
| 76 | Untangling the web of European regulations for the preparation of unlicensed radiopharmaceuticals. <i>Nuclear Medicine Communications</i> , 2015, 36, 414-422.   | 1.1 | 28        |
| 77 | Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. <i>Psychopharmacology</i> , 2015, 232, 3443-3453.   | 3.1 | 55        |
| 78 | A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [18F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 192-202.   | 3.0 | 17        |
| 79 | Synthesis and Evaluation in Rats of the Dopamine D2/3 Receptor Agonist 18F-AMC20 as a Potential Radioligand for PET. <i>Journal of Nuclear Medicine</i> , 2015, 56, 133-139.   | 5.0 | 6         |
| 80 | Potential applications for sigma receptor ligands in cancer diagnosis and therapy. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2015, 1848, 2703-2714.  | 2.6 | 127       |
| 81 | PET Imaging of Adenosine A <sub>1</sub> Receptor Occupancy. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1918-1918.  | 5.0 | 2         |
| 82 | Ex Vivo Characterization of a Novel Iodine-123-Labeled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D2/3 Receptors. <i>International Journal of Molecular Imaging</i> , 2014, 2014, 1-10.  | 1.3 | 0         |
| 83 | Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors. <i>EJNMMI Research</i> , 2014, 4, 53.   | 2.5 | 4         |
| 84 | Cerebral adenosine A1 receptors are upregulated in rodent encephalitis. <i>NeuroImage</i> , 2014, 92, 83-89.   | 4.2 | 9         |
| 85 | Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with 11C-SA4503 and microPET. <i>Psychopharmacology</i> , 2014, 231, 3997-4006.  | 3.1 | 27        |
| 86 | cerebral beta-adrenoceptors. <i>Nuclear Medicine and Biology</i> , 2014, 41, 203-209.  | 0.6 | 3         |
| 87 | Synthesis and Preclinical Evaluation of 2-(2-Furanyl)-7-[2-[4-[4-(2-[ <sup>11</sup> C]methoxyethoxy)phenyl]-1-piperazinyl]ethyl]7H-pyrazolo[4,3-e][1,2,4]triazol-6-yl]-[ <sup>11</sup> C]Preladenant as a PET Tracer for the Imaging of Cerebral Adenosine A <sub>2A</sub> Receptors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9204-9210. | 6.4 | 29        |
| 88 | Imaging the Folate Receptor on Cancer Cells with <sup>99m</sup> Tc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging. <i>Journal of Nuclear Medicine</i> , 2014, 55, 701-704.  | 5.0 | 59        |
| 89 | Development of [ <sup>18</sup> F]-Labeled Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH442416) Analogs for the Imaging of Cerebral Adenosine A <sub>2A</sub> Receptors with Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6765-6780.  | 6.4 | 30        |
| 90 | Use of <sup>11</sup> C-MPDX and PET to Study Adenosine A <sub>1</sub> Receptor Occupancy by Nonradioactive Agonists and Antagonists. <i>Journal of Nuclear Medicine</i> , 2014, 55, 315-320.   | 5.0 | 16        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 615-620.  | 1.0 | 44        |
| 92  | Synthesis and Characterization of a Novel Series of Agonist Compounds as Potential Radiopharmaceuticals for Imaging Dopamine D <sub>2/3</sub> Receptors in Their High-Affinity State. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 391-410.   | 6.4 | 12        |
| 93  | Small Molecule PET-Radiopharmaceuticals. <i>Current Pharmaceutical Design</i> , 2014, 20, 2268-2274.   | 1.9 | 11        |
| 94  | Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer. <i>Amino Acids</i> , 2013, 44, 543-553.   | 2.7 | 24        |
| 95  | Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 135-154.  | 3.0 | 34        |
| 96  | Application of 99mTechnetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients. <i>Nuclear Medicine and Biology</i> , 2013, 40, 933-938.  | 0.6 | 20        |
| 97  | Synthesis of [18F]RGD-K5 by catalyzed [3+2] cycloaddition for imaging integrin $\alpha_5\beta_3$ expression in vivo. <i>Nuclear Medicine and Biology</i> , 2013, 40, 710-716.  | 0.6 | 15        |
| 98  | In Vivo Responses of Human A375M Melanoma to a $\beta$ Ligand: 18F-FDG PET Imaging. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1613-1620.  | 5.0 | 7         |
| 99  | Small-Animal PET with a $\beta$ -Ligand, <sup>11</sup> C-SA4503, Detects Spontaneous Pituitary Tumors in Aged Rats. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1377-1383.  | 5.0 | 14        |
| 100 | Asymmetric Synthesis of Carbon-11 Labelled $\alpha$ -Amino Acids for PET. <i>Current Organic Chemistry</i> , 2013, 17, 2127-2137.  | 1.6 | 10        |
| 101 | Application of Click Chemistry for PET. <i>Current Organic Chemistry</i> , 2013, 17, 2108-2118.  | 1.6 | 14        |
| 102 | An Update of Radiolabeled Bombesin Analogs for Gastrin-Releasing Peptide Receptor Targeting. <i>Current Pharmaceutical Design</i> , 2013, 19, 3329-3341.   | 1.9 | 48        |
| 103 | Probes for Non-invasive Matrix Metalloproteinase-targeted Imaging with PET and SPECT. <i>Current Pharmaceutical Design</i> , 2013, 19, 4647-4672.  | 1.9 | 65        |
| 104 | <sup>18</sup> F-FEAnGA for PET of $\beta$ -Glucuronidase Activity in Neuroinflammation. <i>Journal of Nuclear Medicine</i> , 2012, 53, 451-458.  | 5.0 | 26        |
| 105 | Evaluation of $\alpha$ -[Methyl-11C]Thiothymidine in a Rodent Tumor and Inflammation Model. <i>Journal of Nuclear Medicine</i> , 2012, 53, 488-494.  | 5.0 | 19        |
| 106 | In Vivo Evaluation of 1-O-(4-(2-Fluoroethyl-Carbamoyloxymethyl)-2-Nitrophenyl)-O- $\beta$ -D-Glucopyronuronate: A Positron Emission Tomographic Tracer for Imaging $\beta$ -Glucuronidase Activity in a Tumor/Inflammation Rodent Model. <i>Molecular Imaging</i> , 2012, 11, 7290.2011.00029. | 1.4 | 9         |
| 107 | Induction of $\beta$ -Glucuronidase Release by Cytostatic Agents in Small Tumors. <i>Molecular Pharmaceutics</i> , 2012, 9, 3277-3285.   | 4.6 | 14        |
| 108 | In vivo evaluation of [18F]FEAnGA-Me: a PET tracer for imaging $\beta$ -glucuronidase ( $\beta$ -GUS) activity in a tumor/inflammation rodent model. <i>Nuclear Medicine and Biology</i> , 2012, 39, 854-863.  | 0.6 | 7         |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 109 | Tailored imaging of islet cell tumors of the pancreas amidst increasing options. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 213-226.   | 4.4  | 9         |
| 110 | Trends on the Role of PET in Drug Development. , 2012, , .   |      | 6         |
| 111 | Multimerization Improves Targeting of Peptide Radio-Pharmaceuticals. <i>Current Pharmaceutical Design</i> , 2012, 18, 2501-2516.   | 1.9  | 15        |
| 112 | The cholinergic system, sigma-1 receptors and cognition. <i>Behavioural Brain Research</i> , 2011, 221, 543-554.   | 2.2  | 78        |
| 113 | Effect of radiotherapy and chemotherapy on bone marrow activity. <i>Nuclear Medicine Communications</i> , 2011, 32, 17-22.   | 1.1  | 27        |
| 114 | <sup>99m</sup> Tc-HYNIC(tricine/TPPTS)-Aca-Bombesin( <sup>74</sup> Br) as a Targeted Imaging Agent with MicroSPECT in a PC-3 Prostate Cancer Xenograft Model. <i>Molecular Pharmaceutics</i> , 2011, 8, 1165-1173.   | 4.6  | 31        |
| 115 | Strain-Promoted Copper-Free Click Chemistry for <sup>18</sup> F Radiolabeling of Bombesin. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 11117-11120.   | 13.8 | 113       |
| 116 | Small-Animal PET Study of Adenosine A <sub>1</sub> Receptors in Rat Brain: Blocking Receptors and Raising Extracellular Adenosine. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1293-1300.   | 5.0  | 24        |
| 117 | VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment. <i>Cancer Research</i> , 2011, 71, 143-153.  | 0.9  | 105       |
| 118 | Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1049-1062.  | 6.4  | 113       |
| 119 | Sigma Receptors in Oncology: Therapeutic and Diagnostic Applications of Sigma Ligands. <i>Current Pharmaceutical Design</i> , 2010, 16, 3519-3537.   | 1.9  | 96        |
| 120 | Carbon-11 Labeled Tracers for In Vivo Imaging of P-Glycoprotein Function: Kinetics, Advantages and Disadvantages. <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 1820-1833.  | 2.1  | 21        |
| 121 | Synthesis and Evaluation of [ <sup>18</sup> F]-FEAnGA as a PET Tracer for <sup>β</sup> -Glucuronidase Activity. <i>Bioconjugate Chemistry</i> , 2010, 21, 911-920.   | 3.6  | 27        |
| 122 | 6-[F-18]Fluoro-Dihydroxyphenylalanine Positron Emission Tomography Is Superior to Conventional Imaging with <sup>123</sup> I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3922-3930. | 3.6  | 153       |
| 123 | Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 199-213.  | 4.4  | 135       |
| 124 | Obituary   Nuclear Medicine and Biology - Volume 36, Issue 2. <i>Nuclear Medicine and Biology</i> , 2009, 36, 233-234.   | 0.6  | 0         |
| 125 | Synthesis and Preclinical Evaluation of Novel PET Probes for P-Glycoprotein Function and Expression. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4524-4532.  | 6.4  | 52        |
| 126 | Phosphoramidite accelerated copper(I)-catalyzed [3 + 2] cycloadditions of azides and alkynes. <i>Chemical Communications</i> , 2009, , 2139.   | 4.1  | 149       |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 127 | Synthesis and preliminary evaluation of (S)-[11C]-exaprolol, a novel $\hat{\iota}^2$ -adrenoceptor ligand for PET. <i>Neurochemistry International</i> , 2008, 52, 729-733.   | 3.8  | 8         |
| 128 | Despite irreversible binding, PET tracer [11C]-SA5845 is suitable for imaging of drug competition at sigma receptorsâ€™The cases of ketamine and haloperidol. <i>Neurochemistry International</i> , 2008, 53, 45-50.                              | 3.8  | 18        |
| 129 | Copper-free â€˜clickâ€™ <sup>TM</sup> : 1,3-dipolar cycloaddition of azides and arynes. <i>Organic and Biomolecular Chemistry</i> , 2008, 6, 3461.  | 2.8  | 102       |
| 130 | Proliferation Markers for the Differential Diagnosis of Tumor and Inflammation. <i>Current Pharmaceutical Design</i> , 2008, 14, 3326-3339.   | 1.9  | 58        |
| 131 | Improved Staging of Patients With Carcinoid and Islet Cell Tumors With <sup>18</sup> F-Dihydroxy-Phenyl-Alanine and <sup>11</sup> C-5-Hydroxy-Tryptophan Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2008, 26, 1489-1495. | 1.6  | 240       |
| 132 | Manipulation of [11C]-5-Hydroxytryptophan and 6-[18F]Fluoro-3,4-Dihydroxy-l-Phenylalanine Accumulation in Neuroendocrine Tumor Cells. <i>Cancer Research</i> , 2008, 68, 7183-7190.   | 0.9  | 54        |
| 133 | Cytotoxicity of $\hat{\iota}^2$ -Receptor Ligands Is Associated with Major Changes of Cellular Metabolism and Complete Occupancy of the $\hat{\iota}^2$ -2 Subpopulation. <i>Journal of Nuclear Medicine</i> , 2008, 49, 2049-2056.               | 5.0  | 24        |
| 134 | Growth Factor/Peptide Receptor Imaging for the Development of Targeted Therapy in Oncology. <i>Current Pharmaceutical Design</i> , 2008, 14, 3340-3347.   | 1.9  | 7         |
| 135 | Rapid Reduction of $\hat{\alpha}1$ -Receptor Binding and 18F-FDG Uptake in Rat Gliomas After In Vivo Treatment with Doxorubicin. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1320-1326.  | 5.0  | 20        |
| 136 | 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. <i>Journal of Nuclear Medicine</i> , 2007, 48, 367-72.  | 5.0  | 34        |
| 137 | Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. <i>Lancet Oncology</i> , The, 2006, 7, 728-734.   | 10.7 | 234       |
| 138 | Effect of fenfluramine-induced increases in serotonin release on [18F]MPPF binding: A continuous infusion PET study in conscious monkeys. <i>Synapse</i> , 2006, 59, 18-26.   | 1.2  | 40        |
| 139 | PET Tracers for Imaging of the Dopaminergic System. <i>Current Medicinal Chemistry</i> , 2006, 13, 2139-2153.   | 2.4  | 136       |
| 140 | Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. <i>Journal of Nuclear Medicine</i> , 2006, 47, 150-4.  | 5.0  | 70        |
| 141 | Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1538-45.   | 5.0  | 20        |
| 142 | Positron Emission Tomography Studies of Human Airways Using an Inhaled $\hat{\iota}^2$ -Adrenoceptor Antagonist, S-11 C-CGP 12388. <i>Chest</i> , 2005, 128, 3020-3027.   | 0.8  | 17        |
| 143 | Evaluation of [11C]SA5845 and [11C]SA4503 for imaging of sigma receptors in tumors by animal PET. <i>Annals of Nuclear Medicine</i> , 2005, 19, 701-709.  | 2.2  | 27        |
| 144 | Positron Emission Tomography Studies on Binding of Central Nervous System Drugs and P-Glycoprotein Function in the Rodent Brain. <i>Molecular Imaging and Biology</i> , 2005, 7, 37-44.   | 2.6  | 48        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. <i>Journal of Nuclear Medicine</i> , 2005, 46, 400-4.  | 5.0 | 108       |
| 146 | Synthesis and evaluation of dopamine D3 receptor antagonist 11C-GR218231 as PET tracer for P-glycoprotein. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1384-92.   | 5.0 | 20        |
| 147 | PET Studies on P-Glycoprotein Function in the Blood-Brain Barrier: How it Affects Uptake and Binding of Drugs within the CNS. <i>Current Pharmaceutical Design</i> , 2004, 10, 1493-1503.  | 1.9 | 159       |
| 148 | Detection and Grading of Soft Tissue Sarcomas of the Extremities with 18F-3-Fluoro-3-Deoxy-L-Thymidine. <i>Clinical Cancer Research</i> , 2004, 10, 1685-1690.   | 7.0 | 93        |
| 149 | Receptor imaging in the thorax with PET. <i>European Journal of Pharmacology</i> , 2004, 499, 1-13.  | 3.5 | 19        |
| 150 | Synthesis and evaluation of a fluorine-18 labeled antisense oligonucleotide as a potential PET tracer for iNOS mRNA expression. <i>Nuclear Medicine and Biology</i> , 2004, 31, 605-612.   | 0.6 | 20        |
| 151 | PET Imaging of Beta-Adrenoceptors in Human Brain: A Realistic Goal or a Mirage?. <i>Current Pharmaceutical Design</i> , 2004, 10, 1519-1536.   | 1.9 | 35        |
| 152 | 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2004, 45, 226-31.   | 5.0 | 70        |
| 153 | Evaluation of cardiac beta-adrenoreceptors in the isolated perfused rat heart using (S)-11C-CGP12388. <i>Journal of Nuclear Medicine</i> , 2004, 45, 471-7.  | 5.0 | 27        |
| 154 | Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. <i>Journal of Nuclear Medicine</i> , 2004, 45, 695-700.  | 5.0 | 189       |
| 155 | Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1677-82.   | 5.0 | 45        |
| 156 | Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1939-45.  | 5.0 | 37        |
| 157 | Evaluation of fluorine-18-labeled alkylating agents as potential synthons for the labeling of oligonucleotides. <i>Applied Radiation and Isotopes</i> , 2003, 58, 469-476.   | 1.5 | 20        |
| 158 | Synthesis and evaluation of 11C- and 18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies. <i>Nuclear Medicine and Biology</i> , 2003, 30, 273-284.  | 0.6 | 54        |
| 159 | Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. <i>Journal of Nuclear Medicine</i> , 2003, 44, 331-5.  | 5.0 | 201       |
| 160 | 3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma?. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1927-32.   | 5.0 | 61        |
| 161 | Correspondence re: H. Barthel et al., 3'-deoxy-3'-[(18)F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. <i>Cancer Res.</i> , 63: 3791-3798, 2003. <i>Cancer Research</i> , 2003, 63, 8558-9; author reply 8560. | 0.9 | 5         |
| 162 | Radiopharmaceutical chemistry for positron emission tomography. <i>Methods</i> , 2002, 27, 208-217.  | 3.8 | 58        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. <i>Journal of Nuclear Medicine</i> , 2002, 43, 167-72.   | 5.0 | 52        |
| 164 | Carbon-11 choline or FDG-PET for staging of oesophageal cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1845-1849.   | 6.4 | 44        |
| 165 | Synthesis and biodistribution of [11C]procaterol, a $\hat{1}^2$ -adrenoceptor agonist for positron emission tomography. <i>Applied Radiation and Isotopes</i> , 2000, 52, 857-863.  | 1.5 | 8         |
| 166 | Quantitative imaging of 5-HT1A receptor binding in healthy volunteers with [18f]p-MPPF. <i>Nuclear Medicine and Biology</i> , 2000, 27, 473-476.  | 0.6 | 35        |
| 167 | Fully automated synthesis module for the high yield one-pot preparation of 6-[11C]fluoro-L-DOPA. <i>Applied Radiation and Isotopes</i> , 1999, 51, 389-394.   | 1.5 | 106       |
| 168 | Visualization of $\hat{1}^2$ -Adrenoceptors Using PET. <i>Molecular Imaging and Biology</i> , 1998, 1, 81-94.   | 0.3 | 17        |
| 169 | Synthesis and Evaluation of (S)-4-(3-(2- $\hat{1}^1$ C)isopropylamino)-2-hydroxypropoxy)-2H-benzimidazol-2-one ((S)-[11C]CGP 12388) and (S)-4-(3-(1- $\hat{1}^1$ C)fluoroisopropyl)amino)-2-hydroxypropoxy)-2H-benzimidazol-2-one ((S)-[18F]Fluoro-CGP) <i>Tj ETQq1 1 0.784314 rgB Chemistry</i> , 2007, 40, 2020-2025. | 0.6 | 8         |
| 170 | (S,S)- and (S,R)-1- $\hat{1}^2$ -[18F]fluorocarazolol, ligands for the visualization of pulmonary $\hat{1}^2$ -adrenergic receptors with PET. <i>Nuclear Medicine and Biology</i> , 1996, 23, 159-167.  | 0.6 | 28        |
| 171 | Synthesis of [11C]methyl magnesium iodide and its application to the introduction of [11C]-N-tert-butyl groups and [11C]-sec-alcohols. <i>Applied Radiation and Isotopes</i> , 1995, 46, 227-231.   | 1.5 | 7         |
| 172 | Synthesis of 6 $\hat{1}^2$ -[18F]Fluoroprogestosterone: A first step towards a potential receptor-ligand for PET. <i>Applied Radiation and Isotopes</i> , 1994, 45, 811-813.  | 1.5 | 11        |
| 173 | Robotic synthesis of l-[1-11C]tyrosine. <i>Applied Radiation and Isotopes</i> , 1994, 45, 821-828.  | 1.5 | 9         |
| 174 | Synthesis and preliminary evaluation of (R,S)-1-[2-((Carbamoyl-4-hydroxy)phenoxy)-ethylamino]-3-[4-(1-[11C]-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propanol ([11C]CGP 20712A) as a selective $\hat{1}^2$ -adrenoceptor ligand for PET. <i>Nuclear Medicine and Biology</i> , 1994, 21, 211-217.               | 0.6 | 27        |
| 175 | Synthesis and evaluation of 1- $\hat{1}^2$ -[18F]fluorometoprolol as a potential tracer for the visualization of $\hat{1}^2$ -adrenoceptors with PET. <i>Nuclear Medicine and Biology</i> , 1993, 20, 637-642.  | 0.6 | 22        |
| 176 | Carbon-11 labelled tyrosine to study tumor metabolism by positron emission tomography (PET). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1986, 12, 321-324.   | 2.1 | 50        |
| 177 | Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D <sub>2</sub> and Histamine H <sub>3</sub> Receptors: A PET Study in Healthy Rats. <i>Molecular Pharmaceutics</i> , 0, , .   | 4.6 | 0         |